Sunday, October 1, 2023
10/1/2023
PROJECT(SUMMARY/ABSTRACT! Colorectal cancer (CRC) is associated with the deaths of over 50,000 adult Americans annually. In the previous award period, we showed that in addition to genetic mutation, disease progression is accompanied by epigenetic changes at gene enhancer elements that switch genes on and off. We term these Variant Enhancer Loci, or VELs. Remarkably, colon tumors from different individuals show a common pattern of enhancers that are recurrently activated across patient samples. These recurrently activated enhancers constitute a signature of CRC. In this competing renewal application, we will investigate three non-mutually exclusive hypotheses to uncover the mechanism by which these signature VELs form in CRC. Specific Aim 1 tests the hypothesis that the VELs are a direct consequence of mutations in canonical CRC oncogenes and tumor suppressors. This hypothesis will be tested through H3K27ac ChIP-seq analysis of the enhancer epigenome in human intestinal organoids in which each of known CRC driver genes were sequentially mutated via CRISPR/Cas9 to recapitulate the adenoma- carcinoma sequence predicted by the Vogelgram. Specific Aim 2 tests the hypothesis that transcription factors drive formation of the signature VELs. This hypothesis will be tested through knockdown and overexpression of transcription factors that bind to the signature VELs in CRC cell lines and intestinal organoid models, followed by analysis of chromatin at CRC signature VELs. Specific Aim 3 tests the hypothesis that somatic indel mutations in enhancer elements drive VEL formation. CRISPR-Cas9 genome editing strategies will be used to correct or introduce candidate enhancer-creating indel mutations in CRC cell lines, followed by functional analysis of enhancer activity. Lastly, we propose a fourth Aim to assess whether VELs are required for tumorigenicity of CRC. CRISPR-Cas9-based strategies will be used to disrupt signature VELs in CRC cell lines, followed by quantification of their growth in mouse xenografts relative to unedited control cells. We expect to gain fundamental insights to epigenetic enhancer dysregulation as a root cause of CRC tumorigenesis that could lay the foundation for targeted therapies for patients. !
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
